Alerta

一组特异性结合并检测大鼠IL-1R1的单克隆抗体及检测试剂盒

Resumen de: CN122705737A

0001 本发明提供了一组特异性结合并检测大鼠IL‑1R1的单克隆抗体及检测试剂盒，属于免疫学检测技术领域。本发明提供了一组可特异性结合并检测大鼠白介素1受体1型蛋白（IL‑1R1）的单克隆抗体，所述单克隆抗体以大鼠来源IL‑1R1（rat IL‑1R1）为抗原通过免疫后得到，尤其是单克隆抗体MM08H和MM10H均与rat IL‑1R1结合良好，经配对检测发现，鼠单克隆抗体MM10H可作为包被抗体，通过显色催化酶标记的单克隆抗体MM08H可作为检测抗体，可将所述单克隆抗体用于rat IL‑1R1的免疫学检测。本发明利用所述单克隆抗体构建了rat IL‑1R1的免疫学检测试剂盒，具有良好的检测重复性和稳定性；最低检测限为4.33pg/ml，检测灵敏度良好。

抗eMTBR-tau243片段V256剪切位点的单克隆抗体及其应用和产品

Resumen de: CN122705733A

0001 本发明提供了一种抗eMTBR‑tau243片段V256剪切位点的单克隆抗体及其应用和产品，涉及生物技术领域。本发明提供的单克隆抗体的可变区包括：氨基酸序列如SEQ ID NO.1所示的互补决定区CDR1‑VH、氨基酸序列如SEQ ID NO.2所示的互补决定区CDR2‑VH、氨基酸序列如SEQ ID NO.3所示的互补决定区CDR3‑VH、氨基酸序列如SEQ ID NO.4所示的互补决定区CDR1‑VL、氨基酸序列如SEQ ID NO.5所示的互补决定区CDR2‑VL和氨基酸序列如SEQ ID NO.6所示的互补决定区CDR3‑VL，能特异性识别eMTBR‑tau243片段V256剪切位点。

B-异噁唑衍生物、诊断组合物及其相关方法

Resumen de: AU2024401251A1

The present application relates to novel b-isox analogs for use in detecting misfolded proteins associated with neurodegenerative diseases, such as ALS, PD, AD, FTLD, and LATE. The present inventors identified and modified a specific site on the b-isox molecule, which significantly enhances detection capabilities. This modification also allows for the selection of analogs that either exhibit low background interference or alter cellular targets, based on the alteration of a functional group at critical site.

GFAP的ELISA检测试剂盒

Resumen de: CN122705729A

0001 本发明公开了一种GFAP的ELISA检测试剂盒，属于生物医药检测技术领域。本发明提供了一对特异性结合GFAP的兔源单克隆抗体对，其中第一抗体的轻链氨基酸序列如SEQ ID NO:1所示、重链氨基酸序列如SEQ ID NO:2所示，第二抗体的轻链氨基酸序列如SEQ ID NO:3所示、重链氨基酸序列如SEQ ID NO:4所示；所述第一抗体与第二抗体识别GFAP上不同的抗原表位，能够形成双抗体夹心复合物。本发明还提供了包含所述抗体对的ELISA试剂盒、非诊断目的的GFAP检测方法及所述试剂盒在制备检测GFAP试剂中的应用。本发明试剂盒的检测线性范围为1.56～600pg/mL，检测下限为1.56pg/mL，具有灵敏度高、特异性强、重复性好的优点，适用于GFAP相关疾病的早期辅助诊断和科研定量分析。

一种检测低丰度蛋白的方法

Resumen de: CN122690127A

本发明公开了一种检测低丰度蛋白的方法，包括S1、将磁球偶联待测蛋白的捕获抗体和磷酸末端的寡核苷酸链段，得到捕获待测蛋白的微球、将捕获待测蛋白的微球、待测样品和生物素化检测抗体混合孵育；S2、酶标记，加入SA‑T4 PNKP酶，使捕获待测蛋白的微球表面标记T4 PNKP酶；S3、去磷酸化反应，洗去未结合的SA‑T4 PNKP酶，加入维生素B7置换结合在待测蛋白的微球表面的SA‑T4 PNKP，并激活T4 PNKP的去磷酸化性能，使得待测蛋白的微球表面的磷酸基团去磷酸化为羟基；S4、TdT信号放大，加入TdT酶和dTTP底物，识别待测蛋白的微球表面的羟基并进行polyT链延长；S5、荧光标记；S6、检测荧光强度以评估待测蛋白浓度；本发明提供了操作更为便捷，检测灵敏度高的低丰度蛋白的检测方法。

神经自身免疫疾病的诊断

Resumen de: EP3415909A1

0001 The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.

作为神经退行性疾病的诊断和预后的标志物的p53翻译后修饰

Resumen de: US2022034912A1

The present invention refers to p53 sequence and post translational modifications (PTMs) and to their use as biomarkers in the diagnosis of neurodegenerative disease and cognitive decline and/or in the prognosis of Alzheimer's disease at different stages and/or of neurodegenerative disease in a biological sample. The invention also provides for a 1) diagnostic method based on a highly accurate mass spectrometry analysis for the diagnosis of neurodegenerative disease, including Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), fronto-temporal dementia (FTD), Lewi's Body (LB), and vascular dementia (VD) in a subject, by evaluating the PTMs to the said p53 linear sequence protein and possible cut of its full sequence specifically in human plasma of patients; and 2) prognosis of AD in CU and MCI patients.

婴幼儿的特应性皮炎发病风险预测用蛋白标志物的制备方法

Resumen de: WO2025169281A1

Provided are a method for preparing a protein marker for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization in infants, and a method for predicting the risk of developing atopic dermatitis or the risk of allergen sensitization using said protein marker.　More specifically, the method for preparing a protein marker for predicting the risk of developing atopic dermatitis includes recovering at least one kind of protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2 and PRG2 from a sample collected from the skin of an infant subject.

一种基于Si@Ag/Pt纳米酶的双模态检测Aβ40寡聚体的试剂盒、方法、系统及其应用

Resumen de: CN122690124A

0001 本发明公开了一种基于Si@Ag/Pt纳米酶的双模态检测Aβ<40>寡聚体的试剂盒、方法、系统及其应用。本发明所述试剂盒包括：包被有捕获抗体的固相载体，所述捕获抗体能够与待测样本中的Aβ<40>寡聚体特异性结合；检测探针，所述检测探针为Aβ<40>寡聚体特异性识别分子修饰的Si@Ag/Pt纳米酶探针，对待测样本中的Aβ<40>寡聚体进行捕获与信号转导；任选地，包括用于比色检测的显色底物。本发明将Aβ<40>寡聚体特异性识别分子修饰的Si@Ag/Pt纳米酶探针应用于夹心免疫分析中，利用同一探针兼具的强光散射特性和高效类过氧化物酶活性，在同一检测体系中实现对目标物的明场成像颗粒计数与催化比色双模式信号输出。两种模式独立定量、结果互验，极大地提升了检测的可靠性。

镁离子在缓解冻存样本检测偏差中的应用

Resumen de: CN122690133A

0001 本发明提供了镁离子在缓解冻存样本检测偏差中的应用，涉及免疫检测领域。本发明通过添加镁离子有效缓解了化学发光免疫分析法检测过程中冻存样本与非冻存样本的检测偏差，提高了临床检测的准确性和可靠性。

特应性皮炎鉴别用蛋白标志物的制备方法

Resumen de: WO2025169282A1

Provided are a method for preparing a protein marker for differentiating atopic dermatitis and other skin diseases, and a method for discriminating atopic dermatitis and other skin diseases using said protein marker.　More specifically, the method for preparing a protein marker for differentiating atopic dermatitis and other skin diseases includes collecting, from a sample collected from the skin of a subject, at least one protein selected from FGG, FGA, FGB, FN1, IGHG1, IGHG2, IGHG3, IGHG4, C3, C4B, C7, CFB, CFH, EPX, CLC, RNASE3, RNASE2, and PRG2.

D- Method for Diagnosing Neurodegenerative Brain Diseases Using D-Amino Acid Metabolic Enzymes

Resumen de: KR20260133425A

본 발명은 D-아미노산 대사 효소인 세린 라세메이스(Serine racemase, SR) 및 D-아미노산 산화효소(D-Amino acid oxidase, DAAO)를 이용한 신경 퇴행성 뇌질환 진단 방법에 관한 것으로, 알츠하이머병(AD) 및 파킨슨병(PD) 환자의 혈장 샘플에서 SR 및 DAAO의 활성이 건강한 사람(HC) 대비 현저히 증가함을 확인하였으며, 이를 신경 퇴행성 질환의 바이오마커로 활용할 수 있음을 제시한다. 특히, 본 방법은 혈액 샘플을 이용하는 비침습적 방식으로, 기존의 고가이며 절차가 복잡한 영상 진단법 및 침습적 검사법의 한계를 극복하여 신경 퇴행성 뇌질환을 보다 신속하고 경제적으로 진단할 수 있으며, 치료제 스크리닝에 활용하여 우수한 효과를 갖는 신약 개발에 기여할 수 있다.

3D BIOPRINTED MODEL FOR QUANTIFYING NEURITE OUTGROWTH

Resumen de: WO2026183546A1

A three-dimensional (3D) bioprinted model of a forebrain cortex is designed to quantify neurite outgrowth across a hydrogel bridge. The 3D bioprinted model includes two cell-laden compartments formed using a first hydrogel matrix, separated by a hydrogel bridge formed from a second, stiffer hydrogel matrix. The model may fit within standard 96-well plate formats, enabling medium-throughput screening applications. The model was validated using Alzheimer's disease forebrain cortical populations, demonstrating significant reductions in neurite outgrowth from Alzheimer's disease populations compared to controls.

Amanita Muscaria Mushroom Extracts and Products, and Improved Processes for Producing Extracts of Amanita Muscaria Mushrooms at Kilogram Scale

Resumen de: US20260256858A1

0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.

AN AUTOMATED AND HIGH-THROUGHPUT ANALYZER METHOD FOR A BRAIN DERIVED TAU (BD-TAU) IMMUNOASSAY

Resumen de: WO2026183240A1

The presently described and claimed technology relates to high-throughput automated methods for detecting brain derived tau (BD-tau) in a biological sample using an immunoassay analyzer.

NFL530 PEPTIDE RATIOS AS BIOMARKERS IN NEUROLOGICAL CONDITIONS AND METHODS OF USE THEREOF

Resumen de: WO2026183555A1

Methods of treating a neurodegenerative disease in a subject in need thereof are provided. Exemplary methods include providing a biological sample from the subject; measuring an NfL530 peptide concentration in the biological sample; measuring at least one of an NfL284 peptide concentration and an NfL101 peptide concentration in the biological sample; determining at least one of an NfL530/NfL284 ratio and an NfL530/NfL101 ratio; and treating the subject based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio. In some embodiments, the biological sample is selected from whole blood, plasma, and cerebrospinal fluid. In some embodiments, the subject is determined to have ALS based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio.

METHODS FOR IDENTIFYING AND VALIDATING CELL-TYPE SPECIFIC EXTRACELLULAR VESICLE PROTEINS

Resumen de: WO2026183319A1

Described herein are methods of identifying cell-type specific proteins that are transmembrane on or internal to extracellular vesicles (EVs).

MICROGLIA-SUFFICIENT BRAIN ORGANOIDS

Resumen de: US20260258354A1

The present invention relates to a method for generating a microglia-sufficient brain organoid comprising the step of incubating primitive-like macrophage cells with a brain organoid that is between about 15 to about 30 days old in cerebral organoid medium comprising CSF-1 in a low attachment cell culture vessel to generate microglia cells. The present invention also relates to a microglia-sufficient brain organoid obtained by the method as described herein.

ADAPTATION OF NAPPA FOR SURFACE PLASMON RESONANCE IMAGING ANALYSES

Resumen de: US20260259203A1

0000 Disclosed is a method that combines high throughput and flexible nature of a cell-free protein microarray with the quantitative capability of surface plasmon resonance to detect>400 different protein interactions in <1 hour. A method of detecting interactions between a targeting agent and one or more proteins of interest is disclosed. The method includes producing a set of proteins of interest using a cell-free protein expression system; providing the set of proteins of interest on a protein microarray wherein each spot in the array comprises a protein of interest; contacting the protein microarray with a targeting agent that binds to one or more of the set of proteins of interest; and detecting the binding of the targeting agent to the set of proteins of interest using surface plasmon resonance imaging (SPRi), thereby detecting the targeting agent and one or more proteins of interest in the micro array.

Methods for detecting AAV

Resumen de: AU2026216833A1

24521425_1 (GHMatters) P44915AU02 Provided herein are methods for determining the serotype of a virus particle and/or or determining the heterogeneity of a virus particle (e.g., an AAV particle). In other embodiments, the invention provides methods to determine the heterogeneity of AAV particles. In some aspects, the invention provides viral particles (e.g., rAAV particles) with improved stability and/or improved transduction efficiency by increasing the acetylation and/or deamidation of capsid proteins. ug u g

BIOSENSOR MICROARRAY COMPOSITIONS AND METHODS

Resumen de: US20260259204A1

Described herein are biosensor microarrays comprising detector polypeptide monolayers substantially free of contaminants. Also provided are methods for generation of such biosensor microarrays by capture of polypeptides by arrays comprising capture moieties and associated sensors.

THERAPEUTIC COMBINATIONS OF DRUGS, COMPANION DIAGNOSTICS AND METHODS FOR DOSAGING AND USING THEM

Resumen de: US20260256717A1

In alternative embodiments, provided are drugs and companion diagnostics, or therapeutic drug combinations and a companion diagnostic comprising a dried blood spot or a volumetric dried blood spot, or an at-home high-volume liquid blood, collection device, including products of manufacture and kits, and methods, for using them. In alternative embodiments, provided are novel methods for dosaging therapeutic drug compositions. In alternative embodiments, provided are artificial intelligence (AI)-enabled therapeutic drug compositions (bMEDs™), including bMEDs™ amifampridine for Lambert Eaton Myasthenic Syndrome (LEMS), bMEDs™ deflazacort to Duchenne Muscular Dystrophy (DMD), bMEDs™ propranolol for Infantile Hemangioma, bMEDs™ serabelisib for PIK3CA-Related Overgrowth Spectrum (PROS), bMEDs™ sirolimus for Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon (“KHE w/KMP”), bMED™ everolimus for TSC-associated epilepsy, TSC-associated SEGA, TSC-associated renal angiomyolipoma, breast cancer, pNET, renal cancer, or allograph organ rejection prophylaxis, and bMEDs™ for rare diseases as provided herein.

PROTEIN BIOMARKERS FOR LANADELUMAB TREATMENT

Resumen de: US20260259227A1

0000 Provided herein are methods for determining whether a disorder is susceptible to treatment with a plasma kallikrein inhibitor and methods for identifying a subject as a candidate for treatment with a plasma kallikrein inhibitor. Provided herein are methods of identifying a subject as having or being at risk for a disorder and methods of treating a disorder in a subject. Also provided herein are methods of evaluating effectiveness of a treatment in a subject.

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE CONDITIONS

Resumen de: US20260258105A1

0000 The disclosure relates to the engineering of IL-35 cytokine polypeptides to achieve improved therapies for inflammatory diseases and conditions. Accordingly, aspects of the disclosure relate to a polypeptide comprising SEQ ID NO:2, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:2, wherein the one or more amino acid substitutions comprise K23, R74, R195, R197, or combinations thereof. Further aspects relate to a polypeptide comprising SEQ ID NO:4, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:4, wherein the one or more amino acid substitutions comprise C74. Further aspects relate to a polypeptide comprising SEQ ID NO:6, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO:6, wherein the one or more amino acid substitutions comprise C34.

BIOMARKER FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE AND USE THEREOF

Nº publicación: US20260258495A1 03/09/2026

Solicitante:

DAEGU GYEONGBUK INST OF SCIENCE AND TECHNOLOGY [KR]
DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

Resumen de: US20260258495A1

The present invention relates to a biomarker for the early diagnosis of Alzheimer's disease and a use thereof, and more particularly, the present invention relates to: a biomarker composition for the early diagnosis of Alzheimer's disease, the biomarker composition comprising one or more genes selected from the group consisting of alpha-2-macroglobulin (A2M), creatine kinase M-type (CKM), filamin-A (FLNA), integral alpha-IIb (ITGA2B), alpha-1-acid glycoprotein 2 (ORM2), phospholipid transfer protein (PLTP), haptoglobin (HP), sulfhydryl oxidase 1 (QSOX1), protein-glutamine gamma-glutamyltransferase 2 (TGM2), filamin C (FLNC), heat shock protein 70 (HSP70) and lysomal alpha-mannosidase (MAN2B1), or a protein expressed from the genes; a method for the early diagnosis of Alzheimer's disease; a diagnostic kit for the early diagnosis of Alzheimer's disease; and a method for providing information for predicting and diagnosing Alzheimer's disease.